Analyst Price Target is $23.00
▲ +212.08% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Biomea Fusion in the last 3 months. The average price target is $23.00, with a high forecast of $27.00 and a low forecast of $13.00. The average price target represents a 212.08% upside from the last price of $7.37.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Biomea Fusion.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.